Lugano, Switzerland, December 10, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to be able, once again, to support conferences focusing on cachexia. Helsinn has supported and participated in cachexia themed conferences for a number of years and is proud to be a sponsor this year of the virtual 5th Cancer Cachexia Conference, which was held on 10-11 September 2020, and the 13th International Sarcopenia and Muscle Wasting Digital Conference on Cachexia (SCWD), which will take place as a virtual event on 11-13th December 2020.
For many years Helsinn has been aware of cachexia and muscle wasting and how they represent an increasing burden for health-care systems, cancer patients and their families and healthcare professionals. It is therefore important to increase awareness and education around these severely debilitating conditions. In light of COVID-19 pandemic, SCWD and the Cancer Cachexia Society decided to create virtual conferences, ensuring the international community keeps abreast with the latest advancements in these important disease areas.
Riccardo Braglia, Group Vice Chairman and CEO at Helsinn commented: “We are pleased to be able to support these important cachexia conferences once again. At Helsinn, we understand the importance of awareness and education around these disease areas, and both conferences are key to spreading knowledge and sharing the latest research. We hope that as a result of these events in September and December, there will be concrete improvements in the management of cachexia, sarcopenia and frailty resulting from chronic and acute diseases.” To learn more about the upcoming SCWD Digital Conference and read the agenda, visit the website here: https://society-scwd.org/conference-information/
Helsinn is a privately-owned Swiss Pharma Company which, since 1976, has been improving the lives of patients, guided by core family values of respect, integrity and quality. The Group has an extensive portfolio of marketed innovative cancer and rare disease therapies, a robust drug development pipeline and ambitions to further accelerate its growth through in-licensing and acquisition to address unmet medical needs. Helsinn operates a unique integrated licensing business model, achieving success with over 80 long-standing partners in 190 countries, who share our values. The Group’s pharmaceutical business, (Helsinn Healthcare) is headquartered in Lugano, Switzerland with operating subsidiaries in the U.S. (Helsinn Therapeutics US) and China (Helsinn Pharmaceuticals China) which market the Group’s products directly in these countries. The Group has additional operating subsidiaries in Switzerland (Helsinn Advanced Synthesis, an active pharmaceutical ingredient manufacturer) and Ireland (Helsinn Birex Pharmaceuticals, a drug product manufacturer). Helsinn Investment Fund was created to enhance the future of healthcare by providing funding and strategic support to innovative companies.
Helsinn Group plays an active and central role in promoting social transformation in favor of people and the environment. Corporate social responsibility is at the heart of everything we do which is reinforced in the company’s strategic plan by a commitment to sustainable growth.
To learn more about Helsinn Group please visit www.helsinn.com
Group Head of Communication
Tel: +41 (0) 91 985 21 21